Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
| Autor: | Elvira Buxó, Raquel Hernández, Marcelo Garrido, Mónica Granja, Alicia Hurtado, Olbia Serra, Rosario Vidal Tocino, Ismael Macias, Almudena Cotes Sanchís, Virginia Arrazubi, Ana Custodio, Juana María Cano, Javier Gallego, Avinash Ramchandani, Ana Montes, Paula Jiménez-Fonseca, Juan Diego Cacho, Marta Martín Richard, P. Reguera, Carlos F. Lopez, Alberto Carmona-Bayonas, Laura Visa, Carolina Hernández Pérez, Nieves Martinez Lago, Gema Aguado, María Luisa Limón, Alfonso Martín Carnicero, Paola Pimentel, Flora López, Aitor Azkarate |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male sistema de registros humanos Cancer Treatment Platinum Compounds Gastroenterology Metastasis Medicaments antineoplàstics 0302 clinical medicine Antineoplastic Agents Immunological Quality of life Trastuzumab Basic Cancer Research Antineoplastic Combined Chemotherapy Protocols Medicine and Health Sciences Medicine Registries antineoplásicos mediana edad neoplasias gástricas Aged 80 and over anciano Multidisciplinary protocolos de quimioterapia antineoplásica combinada Advanced gastric cancer Middle Aged adulto análisis de supervivencia Chemistry Oncology Qualitat de vida 030220 oncology & carcinogenesis Physical Sciences Population study Female compuestos de platino medicine.drug Research Article Chemical Elements Adult medicine.medical_specialty Stomach cancer Science Estómac-- Malalties Antineoplastic Agents Ramucirumab 03 medical and health sciences Metàstasi Stomach Neoplasms Internal medicine Gastrointestinal Tumors Humans Survival analysis Platinum Aged Second line treatment Aparell digestiu--Càncer--Registres business.industry Càncer d'estómac Cancers and Neoplasms medicine.disease Antineoplastic Agents Phytogenic Survival Analysis Drug Utilization Health Care Gastric Cancer 030104 developmental biology Metastatic Tumors Quality of Life business |
| Zdroj: | PLoS ONE, Vol 15, Iss 7, p e0235848 (2020) Dipòsit Digital de la UB Universidad de Barcelona PLoS One r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname r-FISABIO. Repositorio Institucional de Producción Científica PLoS ONE r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| ISSN: | 1932-6203 |
| Popis: | Background Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. Materials and methods The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). Results 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's tau = 0.613), lower in those subjects who received second-line (Kendall's tau = 0.539), especially with ramucirumab+CT (Kendall's tau = 0.413). Conclusion This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines. We thank Priscilla Chase Duran for editing the manuscript, Natalia Cateriano, Miguel Vaquero, and IRICOM S.A. for supporting the registry website. We are indebted to all patients, as well as to AGAMENON centres and investigators who particpated in this research and made it possible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|